-
Small Business Grant Funds R&D on New Antibiotics
A spin-off company from University of Utah received funding to develop a new antibiotic that targets the genetics of bacteria becoming resistant to antibiotics.
-
RNA Technology Licensed for Cystic Fibrosis Therapy
Two biotechnology companies are collaborating on treatments for cystic fibrosis that use genetic material to address underlying causes of the inherited disease.
-
New Leukemia Target, Drug Candidate Discovered
An industry-academic research team identified a new target for acute myeloid leukemia, and tested a new drug that stops the growth of these cancer cells.
-
RNA Technology Allows for Fast Vaccine Development
Engineers at MIT designed a process using genetic material in nanoscale particles for vaccines that protected against dangerous diseases with a single dose.
-
Independence Day 2016
It’s the Fourth of July, a.k.a. Independence Day, in the U.S. today, so Science & Enterprise is taking the day off.
-
Bacterial-Biopolymer Delivery System Designed for Vaccines
A biotechnology company and university lab developed a vaccine delivery technique that induces an immune response, combining bacteria and a polymer material.
-
Hundreds of U.S. Clinics Found Selling Stem Cell Services
A comprehensive Internet search finds nearly 600 clinics in the U.S. claiming to offer stem cell treatments, many having dubious scientific or medical validity.
-
Protein Biotech Lands $51.5M in First Venture Round
A spin-off enterprise from Harvard developing therapies that block signaling proteins causing disease is raising $51.5 million its first venture funding round.
-
Radiation Enhances Nanoparticle Cancer Treatments
Targeting tumors with chemotherapy delivered in nanoparticles, preceded with radiation, was shown in lab mice to boost treatments in a range of cancers.
-
Moderna, Merck Partner on Personal Cancer Vaccines
29 June 2016. Biotechnology company Moderna Therapeutics and drug maker Merck are developing therapeutic vaccines using messenger RNA that address unique genetic patterns in patients’ tumors. The deal is expected to bring Moderna an immediate payment of $200 million, and the chance to earn further payments to develop cancer treatments combining Moderna’s technology with an…